{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:16:18Z","timestamp":1793049378648,"version":"4.5.0"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a rare genetic disorder caused by decreased or absent dystrophin gene leading to progressive muscle degeneration and weakness in young boys. Disease progression models for the North Star Ambulatory Assessment (NSAA), a functional measurement widely used to assess outcomes in clinical trials, were developed using a longitudinal population modeling approach. The relationship between NSAA total score over time, loss of ambulation, and potential covariates that may influence disease progression were evaluated. Data included individual participant observations from an internal placebo\u2010controlled phase II clinical trial and from the external natural history database for male patients with DMD obtained through the Cooperative International Neuromuscular Research Group (CINRG). A modified indirect response model for NSAA joined to a loss of ambulation (LOA) time\u2010to\u2010event model described the data well. Age was used as the independent variable because ambulatory function is known to vary with age. The NSAA and LOA models were linked using the dissipation rate constant parameter from the NSAA model by including the parameter as a covariate on the hazard equation for LOA. No covariates were identified. The model was then used as a simulation tool to explore various clinical trial design scenarios. This model contributes to the quantitative understanding of disease progression in DMD and may guide model\u2010informed drug development decisions for ongoing and future DMD clinical trials.<\/jats:p>","DOI":"10.1002\/psp4.12921","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T09:58:40Z","timestamp":1675159120000},"page":"375-386","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease progression modeling of the North Star Ambulatory Assessment for Duchenne Muscular Dystrophy"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6547-2186","authenticated-orcid":false,"given":"Jennifer E.","family":"Hibma","sequence":"first","affiliation":[{"name":"Global Product Development Pfizer Inc.  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4197-4085","authenticated-orcid":false,"given":"Priya","family":"Jayachandran","sequence":"additional","affiliation":[{"name":"Global Product Development Pfizer Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Neelakantan","sequence":"additional","affiliation":[{"name":"Global Product Development Pfizer Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-1577","authenticated-orcid":false,"given":"Lutz O.","family":"Harnisch","sequence":"additional","affiliation":[{"name":"Global Product Development Pfizer Inc.  Sandwich, Kent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90579-4"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7400221"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004347"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.35810"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31822623f1"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.4155\/cli.11.113"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-8966(91)90039-U"},{"key":"e_1_2_11_9_1","first-page":"1119","article-title":"Prevalence of Duchenne\/Becker muscular dystrophy among males aged 5\u201324\u2009years \u2010 four states, 2007","volume":"58","author":"Romitti P","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21544"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1542\/pir.27.3.83"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2011.03939.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2009.06.368"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pri.520"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318225ab2e"},{"key":"e_1_2_11_16_1","unstructured":"Sarepta Therapeutics Inc.Exondys 51 (eteplirsen) prescribing information.2016[cited 2022 February 23] Available from:https:\/\/www.exondys51hcp.com\/sites\/default\/files\/2020\u201008\/EXONDYS51PI.pdf"},{"key":"e_1_2_11_17_1","unstructured":"NS Pharma Inc.Viltepso (viltolarsen) prescribing information.2020[cited 2022 February 23] Available from:https:\/\/www.viltepso.com\/prescribing\u2010information"},{"key":"e_1_2_11_18_1","unstructured":"Sarepta Therapeutics Inc.Amondys 45 (casimersen) prescribing information.2021[cited 2022 February 23] Available from:https:\/\/amondys45.com\/Amondys45_(casimersen)_Prescribing_Information.pdf"},{"key":"e_1_2_11_19_1","unstructured":"Sarepta Therapeutics Inc.Vyondys 53 (golodirsen) prescribing information.2019[cited 2022 February 23] Available from:https:\/\/www.vyondys53.com\/static\/patient\/assets\/Vyondys53_(golodirsen)_Prescribing_Information.pdf"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-91"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.12220"},{"key":"e_1_2_11_22_1","first-page":"149","article-title":"The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"Ricotti V","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2014.09.015"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15176"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2020.08.013"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221097"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24296"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23807"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32160-8"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002891"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-008-9094-4"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09671-7"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160195"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12753"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4155"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"S864","DOI":"10.1016\/j.jval.2019.09.2456","article-title":"PRO126 a composite prognostic score for time to loss of walking ability in Duchenne muscular dystrophy (DMD)","volume":"22","author":"Goemans N","year":"2019","journal-title":"Value Health"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12921","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:02:55Z","timestamp":1694890975000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/psp4.12921"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12921","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"2022-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}